中国癌症杂志
中國癌癥雜誌
중국암증잡지
CHINA ONCOLOGY
2013年
7期
499-504
,共6页
大肠癌%化疗%标志物%miR-4299%miR-196b
大腸癌%化療%標誌物%miR-4299%miR-196b
대장암%화료%표지물%miR-4299%miR-196b
Colorectal cancer%Chemotherapy%Biomarkers%miR-4299%miR-196b
背景与目的：大肠癌是一种高发病率的恶性肿瘤，化疗可以减少肿瘤的生长和复发。当前较为重要的是探究标志物能够预测化疗耐药标志物，从而帮助确定治疗方案。方法：选取2007年11月-2010年5月复旦大学附属肿瘤医院大肠外科Ⅳ期大肠癌患者手术标本，术后患者都使用大肠癌术后规范化一线化疗(希罗达+奥沙利铂)。选取化疗耐药与有效癌组织标本各3例共6例使用microRNA芯片检测。筛选出有统计学意义的miRNA：miR-4299、miR-196b、miR-324-5p、miR-455-3p和miR-939，将候选miRNA在100例Ⅳ期大肠癌患者手术癌组织标本中进行real-time PCR验证。结果：通过芯片筛选，共5个miRNA可能与大肠癌一线化疗耐药有关。miR-4299和miR-196b对化疗耐药有显著诊断意义。miR-4299的AUC为0.784，而miR-196b的AUC为0.647。两个联合诊断AUC为0.848，敏感度和特异度分别为67.9%和90.9%。结论：miR-4299和miR-196b有可能作为诊断对大肠癌一线化疗耐药的标志物。
揹景與目的：大腸癌是一種高髮病率的噁性腫瘤，化療可以減少腫瘤的生長和複髮。噹前較為重要的是探究標誌物能夠預測化療耐藥標誌物，從而幫助確定治療方案。方法：選取2007年11月-2010年5月複旦大學附屬腫瘤醫院大腸外科Ⅳ期大腸癌患者手術標本，術後患者都使用大腸癌術後規範化一線化療(希囉達+奧沙利鉑)。選取化療耐藥與有效癌組織標本各3例共6例使用microRNA芯片檢測。篩選齣有統計學意義的miRNA：miR-4299、miR-196b、miR-324-5p、miR-455-3p和miR-939，將候選miRNA在100例Ⅳ期大腸癌患者手術癌組織標本中進行real-time PCR驗證。結果：通過芯片篩選，共5箇miRNA可能與大腸癌一線化療耐藥有關。miR-4299和miR-196b對化療耐藥有顯著診斷意義。miR-4299的AUC為0.784，而miR-196b的AUC為0.647。兩箇聯閤診斷AUC為0.848，敏感度和特異度分彆為67.9%和90.9%。結論：miR-4299和miR-196b有可能作為診斷對大腸癌一線化療耐藥的標誌物。
배경여목적：대장암시일충고발병솔적악성종류，화료가이감소종류적생장화복발。당전교위중요적시탐구표지물능구예측화료내약표지물，종이방조학정치료방안。방법：선취2007년11월-2010년5월복단대학부속종류의원대장외과Ⅳ기대장암환자수술표본，술후환자도사용대장암술후규범화일선화료(희라체+오사리박)。선취화료내약여유효암조직표본각3례공6례사용microRNA심편검측。사선출유통계학의의적miRNA：miR-4299、miR-196b、miR-324-5p、miR-455-3p화miR-939，장후선miRNA재100례Ⅳ기대장암환자수술암조직표본중진행real-time PCR험증。결과：통과심편사선，공5개miRNA가능여대장암일선화료내약유관。miR-4299화miR-196b대화료내약유현저진단의의。miR-4299적AUC위0.784，이miR-196b적AUC위0.647。량개연합진단AUC위0.848，민감도화특이도분별위67.9%화90.9%。결론：miR-4299화miR-196b유가능작위진단대대장암일선화료내약적표지물。
Background and purpose: Colorectal cancer (CRC) is the most frequently occurring primary malignant tumor. Chemotherapy can reduce the risk of local and distant relapse. Therefore, it is very important to ifnd new biomarkers that can predict chemoresistant and help in treatment decisions. Methods:In this study, we examined the expression levels of 1 200 human miRNAs in 6 CRC tissues, using miRNA proifling assay arrays. A validation study was done to corroborate a subset of the results, including expression levels of miR-4299, miR-196b, miR-324-5p, miR-455-3p and miR-939, by analyzing 100 specimens of stageⅣcolorectal adenocarcinoma (not respond and respond to the chemotherapy) to quantitative real-time PCR. We modeled the relationship between the expression levels of these miRNAs and the survival rate of 100 CRC patients by Kaplan-Meier method. Results:Expression proifles in CRCs suggested that 5 miRNAs were candidate markers associated with the chemoresistance of colorectal cancer. We found that miR-4299 and-196b had signiifcant diagnostic value for chemoresistance CRC. miR-4299 yielded an AUC (the areas under the ROC curve) of 0.784 and miR-196b yielded an AUC of 0.647 in discriminating CRC from controls. Combined ROC analysis using these 2 miRNAs revealed an elevated AUC of 0.848 with 67.9%sensitivity and 90.9%speciifcity in discriminating chemoresistance CRC. The low level of miR-4299 expression and the high level of-196b expression are signiifcantly correlated with the good survival of CRC patients. Conclusion:These data suggest that miR-4299 and-196b have strong potential as novel biomarkers for chemoresistant detection of colorectal cancer.
